MML Investors Services LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 17.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,674 shares of the medical technology company’s stock after purchasing an additional 13,823 shares during the quarter. MML Investors Services LLC’s holdings in Medtronic were worth $8,532,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Sustainable Insight Capital Management LLC purchased a new position in shares of Medtronic during the 4th quarter valued at $964,000. Actinver Wealth Management Inc. purchased a new position in shares of Medtronic during the 4th quarter valued at $2,101,000. Chesley Taft & Associates LLC grew its holdings in shares of Medtronic by 11.7% during the 1st quarter. Chesley Taft & Associates LLC now owns 10,029 shares of the medical technology company’s stock valued at $913,000 after acquiring an additional 1,050 shares in the last quarter. Wills Financial Group Inc. grew its holdings in shares of Medtronic by 19.3% during the 4th quarter. Wills Financial Group Inc. now owns 18,021 shares of the medical technology company’s stock valued at $1,639,000 after acquiring an additional 2,921 shares in the last quarter. Finally, Stanley Laman Group Ltd. grew its holdings in shares of Medtronic by 2.3% during the 4th quarter. Stanley Laman Group Ltd. now owns 11,702 shares of the medical technology company’s stock valued at $1,064,000 after acquiring an additional 266 shares in the last quarter. 80.10% of the stock is currently owned by institutional investors.

Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Medtronic in a report on Monday, May 27th. UBS Group boosted their price target on shares of Medtronic to $112.00 and gave the company a “buy” rating in a report on Friday. Royal Bank of Canada lowered their price target on shares of Medtronic to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, May 28th. Finally, Wells Fargo & Co upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $100.00 to $110.00 in a report on Tuesday, June 4th. Eight research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $103.95.

Shares of NYSE:MDT opened at $97.50 on Friday. The firm has a market capitalization of $130.76 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 2.51 and a beta of 0.68. Medtronic PLC has a 1 year low of $81.66 and a 1 year high of $100.15. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.59 and a quick ratio of 2.15.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.07. The firm had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.12 billion. Medtronic had a net margin of 15.15% and a return on equity of 14.16%. Medtronic’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company posted $1.42 earnings per share. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

In related news, EVP Hooman Hakami sold 52,664 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $97.49, for a total value of $5,134,213.36. Following the completion of the sale, the executive vice president now directly owns 95,337 shares in the company, valued at $9,294,404.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Hoedt Rob Ten sold 9,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $91.88, for a total transaction of $826,920.00. Following the completion of the sale, the executive vice president now owns 58,785 shares of the company’s stock, valued at $5,401,165.80. The disclosure for this sale can be found here. Insiders sold 72,664 shares of company stock valued at $7,017,683 over the last quarter. 0.28% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/medtronic-plc-nysemdt-holdings-increased-by-mml-investors-services-llc/3042583.html.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Recommended Story: Equity Income

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.